Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Patients With Advanced Solid Tumors

Tundra lists 4 Patients With Advanced Solid Tumors clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07664150

CW-301 FIH Study of CAN016

A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients with Advanced Solid Tumors

Gender: All

Ages: 18 Years - Any

Updated: 2026-07-01

1 state

Patients With Advanced Solid Tumors
NOT YET RECRUITING

NCT07661797

Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.

Gender: All

Ages: 18 Years - Any

Updated: 2026-06-22

Patients With Advanced Solid Tumors
RECRUITING

NCT05835609

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.

Gender: All

Ages: 18 Years - Any

Updated: 2025-08-22

Patients With Advanced Solid Tumors
RECRUITING

NCT05392699

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection. The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.

Gender: All

Ages: 18 Years - Any

Updated: 2022-06-22

Patients With Advanced Solid Tumors